CCR5 gene editing of resting CD4+ T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice

Guohua Yi, Jang Gi Choi, Preeti Bharaj, Sojan Abraham, Ying Dang, Tal Kafri, Ogechika Alozie, Manjunath N. Manjunath, Premlata Shankar

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

CCR5 disruption by zinc finger nucleases (ZFNs) is a promising method for HIV-1 gene therapy. However, successful clinical translation of this strategy necessitates the development of a safe and effective method for delivery into relevant cells. We used non-integrating lentivirus (NILV) for transient expression of ZFNs and pseudotyped the virus with HIV-envelope for targeted delivery to CD4 + T cells. Both activated and resting primary CD4 + T cells transduced with CCR5-ZFNs NILV showed resistance to HIV-1 infection in vitro. Furthermore, NILV transduced resting CD4 + T cells from HIV-1 seronegative individuals were resistant to HIV-1 challenge when reconstituted into NOD-scid IL2rγc null (NSG) mice. Likewise, endogenous virus replication was suppressed in NSG mice reconstituted with CCR5-ZFN-transduced resting CD4 + T cells from treatment naïve as well as ART-treated HIV-1 seropositive patients. Taken together, NILV pseudotyped with HIV envelope provides a simple and clinically viable strategy for HIV-1 gene therapy.

Original languageEnglish (US)
Article numbere198
JournalMolecular Therapy - Nucleic Acids
Volume3
DOIs
StatePublished - Sep 30 2014
Externally publishedYes

Fingerprint

Lentivirus
Zinc Fingers
HIV-1
HIV
T-Lymphocytes
Genetic Therapy
Virus Replication
HIV Infections
Gene Editing
Viruses

Keywords

  • CCR5 gene editing
  • HIV-1 therapy
  • humanized mice
  • non-integrating lentivirus
  • resting CD4+ T cells
  • zinc finger nucleases

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

CCR5 gene editing of resting CD4+ T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice. / Yi, Guohua; Choi, Jang Gi; Bharaj, Preeti; Abraham, Sojan; Dang, Ying; Kafri, Tal; Alozie, Ogechika; Manjunath, Manjunath N.; Shankar, Premlata.

In: Molecular Therapy - Nucleic Acids, Vol. 3, e198, 30.09.2014.

Research output: Contribution to journalArticle

Yi, Guohua ; Choi, Jang Gi ; Bharaj, Preeti ; Abraham, Sojan ; Dang, Ying ; Kafri, Tal ; Alozie, Ogechika ; Manjunath, Manjunath N. ; Shankar, Premlata. / CCR5 gene editing of resting CD4+ T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice. In: Molecular Therapy - Nucleic Acids. 2014 ; Vol. 3.
@article{1390aee0f5204918bc761322fbfad376,
title = "CCR5 gene editing of resting CD4+ T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice",
abstract = "CCR5 disruption by zinc finger nucleases (ZFNs) is a promising method for HIV-1 gene therapy. However, successful clinical translation of this strategy necessitates the development of a safe and effective method for delivery into relevant cells. We used non-integrating lentivirus (NILV) for transient expression of ZFNs and pseudotyped the virus with HIV-envelope for targeted delivery to CD4 + T cells. Both activated and resting primary CD4 + T cells transduced with CCR5-ZFNs NILV showed resistance to HIV-1 infection in vitro. Furthermore, NILV transduced resting CD4 + T cells from HIV-1 seronegative individuals were resistant to HIV-1 challenge when reconstituted into NOD-scid IL2rγc null (NSG) mice. Likewise, endogenous virus replication was suppressed in NSG mice reconstituted with CCR5-ZFN-transduced resting CD4 + T cells from treatment na{\"i}ve as well as ART-treated HIV-1 seropositive patients. Taken together, NILV pseudotyped with HIV envelope provides a simple and clinically viable strategy for HIV-1 gene therapy.",
keywords = "CCR5 gene editing, HIV-1 therapy, humanized mice, non-integrating lentivirus, resting CD4+ T cells, zinc finger nucleases",
author = "Guohua Yi and Choi, {Jang Gi} and Preeti Bharaj and Sojan Abraham and Ying Dang and Tal Kafri and Ogechika Alozie and Manjunath, {Manjunath N.} and Premlata Shankar",
year = "2014",
month = "9",
day = "30",
doi = "10.1038/mtna.2014.52",
language = "English (US)",
volume = "3",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - CCR5 gene editing of resting CD4+ T cells by transient ZFN expression from HIV envelope pseudotyped nonintegrating lentivirus confers HIV-1 resistance in humanized mice

AU - Yi, Guohua

AU - Choi, Jang Gi

AU - Bharaj, Preeti

AU - Abraham, Sojan

AU - Dang, Ying

AU - Kafri, Tal

AU - Alozie, Ogechika

AU - Manjunath, Manjunath N.

AU - Shankar, Premlata

PY - 2014/9/30

Y1 - 2014/9/30

N2 - CCR5 disruption by zinc finger nucleases (ZFNs) is a promising method for HIV-1 gene therapy. However, successful clinical translation of this strategy necessitates the development of a safe and effective method for delivery into relevant cells. We used non-integrating lentivirus (NILV) for transient expression of ZFNs and pseudotyped the virus with HIV-envelope for targeted delivery to CD4 + T cells. Both activated and resting primary CD4 + T cells transduced with CCR5-ZFNs NILV showed resistance to HIV-1 infection in vitro. Furthermore, NILV transduced resting CD4 + T cells from HIV-1 seronegative individuals were resistant to HIV-1 challenge when reconstituted into NOD-scid IL2rγc null (NSG) mice. Likewise, endogenous virus replication was suppressed in NSG mice reconstituted with CCR5-ZFN-transduced resting CD4 + T cells from treatment naïve as well as ART-treated HIV-1 seropositive patients. Taken together, NILV pseudotyped with HIV envelope provides a simple and clinically viable strategy for HIV-1 gene therapy.

AB - CCR5 disruption by zinc finger nucleases (ZFNs) is a promising method for HIV-1 gene therapy. However, successful clinical translation of this strategy necessitates the development of a safe and effective method for delivery into relevant cells. We used non-integrating lentivirus (NILV) for transient expression of ZFNs and pseudotyped the virus with HIV-envelope for targeted delivery to CD4 + T cells. Both activated and resting primary CD4 + T cells transduced with CCR5-ZFNs NILV showed resistance to HIV-1 infection in vitro. Furthermore, NILV transduced resting CD4 + T cells from HIV-1 seronegative individuals were resistant to HIV-1 challenge when reconstituted into NOD-scid IL2rγc null (NSG) mice. Likewise, endogenous virus replication was suppressed in NSG mice reconstituted with CCR5-ZFN-transduced resting CD4 + T cells from treatment naïve as well as ART-treated HIV-1 seropositive patients. Taken together, NILV pseudotyped with HIV envelope provides a simple and clinically viable strategy for HIV-1 gene therapy.

KW - CCR5 gene editing

KW - HIV-1 therapy

KW - humanized mice

KW - non-integrating lentivirus

KW - resting CD4+ T cells

KW - zinc finger nucleases

UR - http://www.scopus.com/inward/record.url?scp=84923339481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923339481&partnerID=8YFLogxK

U2 - 10.1038/mtna.2014.52

DO - 10.1038/mtna.2014.52

M3 - Article

AN - SCOPUS:84923339481

VL - 3

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

M1 - e198

ER -